Commentary|Articles|November 16, 2026

Early Diffuse TGCT Recurrence Puts Systemic Therapy Trade-Offs in Focus

Fact checked by: Matt Flowers
Listen
0:00 / 0:00

During a virtual event, Richard F. Riedel, MD, and participants discussed how monitoring demands, side effects, and patient priorities shape systemic therapy selection after early recurrence of diffuse tenosynovial giant cell tumor.

Diffuse tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm of the synovium, tendon sheath, or bursa that often recurs after surgery, most often in patients diagnosed between 35 and 50 years of age.1 When further operations threaten joint function, 2 inhibitors of the colony-stimulating factor 1 receptor, pexidartinib (Turalio) and vimseltinib (Romvimza), are available. Both have shown activity in randomized, placebo-controlled phase 3 trials, but they differ in dosing schedule, monitoring requirements, and adverse events.

In a virtual Case-Based Roundtable event for oncologists across the eastern US, Richard F. Riedel, MD, a professor of medicine at Duke University School of Medicine and a medical oncologist at the Duke Cancer Institute in Durham, North Carolina, reviewed the trial data behind both agents and moderated discussion of a 42-year-old man whose diffuse disease recurred 6 months after synovectomy. Riedel noted that he considers both agents and that dosing, monitoring, and tolerability weigh heavily in the choice.

Register today to join a Case-Based Roundtable near you.

This article is part 1 of a 2-part series from a Case-Based Roundtable event.

CASE SUMMARY

Patient Presentation

  • 42-year-old man
  • Chief complaint of left knee swelling, stiffness, and pain over several months
  • Duration, 1 year; pain, 5/10 on a visual analog scale (VAS); trauma, none

History

  • One-year history of progressive left knee swelling and stiffness, initially intermittent but now persistent
  • Activity-related pain (VAS 5/10) with occasional episodes of the knee “locking”
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) and activity modification tried without meaningful relief
  • No history of trauma. No fevers, chills, or weight loss. No relevant family history.

Physical Exam

  • General: Well-appearing, no acute distress
  • Left knee: Large, boggy effusion; warmth to palpation; palpable synovial thickening along the medial and lateral joint lines
  • Range of motion: Flexion limited to 100°, mild extension lag
  • Neurovascular: Intact distally
  • Gait: Antalgic gait, avoids full weight-bearing on the left leg

Diagnostic Workup

  • MRI of left knee: Diffuse, lobulated synovial proliferation with characteristic low T2 signal (hemosiderin deposition); disease extends circumferentially around the joint with focal extra-articular extension posteriorly
  • Image-guided biopsy: Confirms diffuse-type TGCT
  • Labs: Complete blood count (CBC), comprehensive metabolic panel (CMP), and liver function tests (LFTs) within normal limits

Initial Treatment

  • Given the diffuse but largely intra-articular distribution of disease, the case was reviewed at a multidisciplinary sarcoma tumor board, and the patient underwent an open total synovectomy
  • Post-operative recovery was uncomplicated, with initial improvement in swelling and range of motion

Current Status and Assessment

  • Timing: 6 months post-synovectomy
  • Interval history: Surveillance MRI reveals early recurrence, with re-accumulation of synovial disease along the posterior capsule; patient reports recurrent swelling and pain (VAS 4/10) with mild functional decline
  • Physical exam: Mild-moderate effusion, warmth, flexion limited to 110°
  • ECOG performance status: 1
  • Labs: Normal CBC, CMP, and LFTs, no contraindication to systemic therapy

Multidisciplinary Assessment

  • Disease has recurred following surgery, with distribution felt to be poorly suited for a second complete resection without meaningful risk to joint function
  • Patient is treatment-naïve to systemic therapy, with normal baseline hepatic function and no comorbidities limiting eligibility
  • After discussion of risks (including hepatotoxicity monitoring requirements) and benefits, the patient is started on pexidartinib, with baseline and scheduled on-treatment monitoring of LFTs per Risk Evaluation and Mitigation Strategy (REMS) requirements

EVENT RECAP

During the event, Ioana Bonta, MD, of Georgia Cancer Specialists in Atlanta, commented that most of her patients with TGCT have had a delay, including uncertainty over whether to biopsy. Alexander Barsouk, MD, of Allegheny Oncology Network in DuBois, Pennsylvania, added that orthopedic oncologists are scarce and called it “like finding [a] needle in a haystack.” Riedel said referral now typically follows an index surgery, whereas in the mid-to-late 2010s he saw patients after 4 or 5 operations.

For this patient, the group weighed a second surgery against systemic therapy. NCCN guidelines list pexidartinib and vimseltinib as preferred category 1 options for TGCT, and imatinib (Gleevec) and nilotinib (Tasigna) as useful in certain circumstances.2 Atif Hussein, MD, of Memorial Cancer Institute in Fort Lauderdale, Florida, said, “I will definitely give him systemic therapy,” while keeping surgery available if the tumor shrank and stayed stable. Riedel said time to recurrence, disease bulk, and surgical morbidity matter, as do patient reluctance to take a daily pill and fertility goals. He asked whether patients should be treated to maximum response and then given a break, adding, “These are questions we don’t really have answers to.”

Riedel presented the relevant trial data on the systemic therapies. In the phase 3 ENLIVEN trial (NCT02371369), 120 patients with symptomatic, advanced TGCT not amenable to surgery were randomly assigned 1:1 to pexidartinib or placebo. At week 25, 39% of those assigned to pexidartinib (24 of 61) had a response by RECIST vs 0 of 59 assigned to placebo (absolute difference, 39%; 95% CI, 27%-53%; P <.0001).3 At a median follow-up of 31.2 months, the objective response rate among all 91 patients who received pexidartinib was 60% by RECIST (95% CI, 50%-70%) in an open-label analysis, and 19.8% had discontinued because of an adverse event. Liver enzymes reached 5 times the upper limit of normal or higher in 18.7%, and 3.3% had findings consistent with mixed or cholestatic hepatotoxicity during the blinded portion.4 That risk is why pexidartinib is dispensed through a REMS program. The label calls for liver tests before starting, weekly for 8 weeks, every 2 weeks for the next month, and every 3 months thereafter, with each dose taken with a low-fat meal.5

Hussein described a man in his mid-30s who developed hair color changes, fatigue, and liver enzyme elevations around week 6; after the drug was held and restarted at a reduced dose, they did not recur.

Vimseltinib was approved in February 2025.1 In the phase 3 MOTION trial (NCT05059262), 123 patients were randomly assigned 2:1 to vimseltinib 30 mg twice weekly or placebo. At week 25, the response rate by RECIST on independent radiological review was 40% (33 of 83) with vimseltinib vs none of 40 with placebo (difference, 40%; 95% CI, 29%-51%; P less than .0001).6 With at least 2 years of follow-up, the on-study response rate was 48% (40 of 83) in patients randomized to vimseltinib and 54% (19 of 35) in those who crossed over.1 Periorbital edema occurred in 48% of 118 patients who received vimseltinib and pruritus in 36%. Riedel said vimseltinib has no REMS program or dietary fat requirement.

Riedel described a patient who improved enough on vimseltinib to stop using a cane but had to stop after 6 months because of periorbital edema despite 2 dose reductions; the patient could not see because of the swelling. Disease control held for more than 6 months off drug. Shivani Dalal, MD, of Memorial Healthcare System in Fort Lauderdale, asked about switching such a patient to pexidartinib. Riedel said he would switch if disease control were still needed, but for a patient responding to and tolerating pexidartinib, “I wouldn’t switch them just for the sake of switching.”

Dalal also raised the question of fertility. Riedel said no data separate the 2 agents on ovarian toxicity and that he refers patients of childbearing potential to a fertility clinic. For a patient who wants to conceive and has limited disease, he considers a repeat synovectomy reasonable to buy time.

Dalal said younger patients often hesitate over long-term treatment, lab monitoring, and fertility, though symptoms improve on therapy. Riedel said responses often come quickly, and “it’s amazing what people are willing to accept in the setting of improvement in their quality of life.” Asked about the pexidartinib REMS program, Dalal said, “I wouldn’t say it’s very cumbersome.” Riedel said hepatotoxicity typically appears within the first 2 months, so the REMS program is a minor inconvenience after that.

Riedel said most people try vimseltinib first for the lighter pill burden and then manage edema as best they can. Ice packs at night are an option; diuretics have helped little. “I have not found something that works really well,” he said.

Participants treated the monitoring and dosing burden of pexidartinib and the edema and pruritus of vimseltinib as the practical trade-offs between 2 active agents, and Riedel said he considers both, with most people starting on vimseltinib for the lighter pill burden.

Register today to join a Case-Based Roundtable near you.

DISCLOSURES: Riedel previously reported funding to the institution for clinical trial support from Aadi Bioscience, Adaptimmune, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, TRACON, and Trillium; consulting fees from Aadi Bioscience, Adaptimmune, Bayer, Blueprint, Boehringer Ingelheim, Daiichi-Sankyo, Deciphera, GSK, NanoCarrier, and SpringWorks; honoraria for lectures from SpringWorks; and travel support for advisory board participation from Deciphera.

REFERENCES
1. Bhadri V, Gelderblom H, Stacchiotti S, et al. Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial. Oncologist. 2026;31(11):oyag421. doi:10.1093/oncolo/oyag421
2. NCCN. Clinical Practice Guidelines in Oncology. Soft tissue sarcoma, version 5.2026. Accessed November 16, 2026. https://tinyurl.com/3fsp7d9x
3. Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478-487. doi:10.1016/S0140-6736(19)30764-0
4. Wagner AJ, Tap WD, Bauer S, et al. Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. Oncologist. 2025;30(7):oyae345. doi:10.1093/oncolo/oyae345
5. Turalio. Prescribing information. Daiichi Sankyo, Inc; revised November 2023. Accessed November 16, 2026. https://tinyurl.com/4w8utft6
6. Gelderblom H, Bhadri V, Stacchiotti S, et al; MOTION Investigators. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10445):2709-2719. doi:10.1016/S0140-6736(24)00885-7

Related to this article